Re-irradiation with SBRT (Stereotactic Body Radiation Therapy) for locoregional unresectable relapse of head and neck cancer: a case report
DOI:
https://doi.org/10.23938/ASSN.0715Keywords:
SBRT. Re-irradiation. Head and neck.Abstract
Patients with an unresectable recurrence of head and neck carcinoma (HNC) have a poor prognosis, with limited treatment options. Recent technical advances allow radiotherapy (RT) to be handled with great precision, making it possible to re-irradiate recurrent tumors by means of stereotactic body radiotherapy (SBRT) with high doses of RT while protecting healthy tissues near the tumor. Although this technique has been used to irradiate different primary tumors and their metastases, SBRT in HNC has had a much slower evolution than in the mentioned locations. This is due to the difficulties in re-irradiating the HNC, because of the expected toxicity as it is a relatively small area with dense vascularization and innervation, and where several senses are located.
We present the first case of a HNC re-irradiated with SBRT in the Complejo Hospitalario de Navarra; the patient showed a complete response and continues to be disease-free sixteen months after the irradiation.
Keywords. SBRT. Re-irradiation. Head and neck.
Downloads
References
.- Patel PR, Salama JK. Reirradiation for recurrent head and neck cancer. Expert Rev Anticancer Ther 2012;12: 1177–1189.
- Clavel M, Vermorken JB, Cognetti F, Cappelaere P, de Mulder PH, Schornagel JH
et al. Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck. A phase III study of the EORTC Head and Neck Cancer Cooperative Group. Ann Oncol 1994;5: 521–526.
- Spencer SA, Harris J, Wheeler RH, Machtay M, Schultz C, Spanos W
et al. RTOG 96-10: reirradiation with concurrent hydroxyurea and 5-fluorouracil in patients with squamous cell cancer of the head and neck. Int J Radiat Oncol Biol Phys 2001;51: 1299–1304.
Langer CJ, Harris J, Horwitz EM, et al. Phase II study of low-dose paclitaxel and cisplatin in combination with split-course concomitant twice-daily reirradiation in recurrent squamous cell carcinoma of the head and neck: results of Radiation Therapy Oncology Group Protocol 9911. J Clin Oncol 2007;25: 4800–4805.
- Román A A, Jodar C, Perez-Rozos A, Gomez-Millan J, et al: The role of stereotactic body radiotherapy in reirradiation of head and neck cancer recurrence. Crit Rev Oncol Hematol. 2018 Feb; 122:194-201.
- Baliga S, Kabarriti R, Ohri N, et al. Stereotactic body radiotherapy for recurrent head and neck cancer: A critical review. Head Neck. 2017 Mar; 39(3): 595-601
- Kodani N, Yamazaki H, Tsubokura T, et al. Stereotactic body radiation
therapy for head and neck tumor: disease control and morbidity outcomes.
J Radiat Res 2011; 52: 24–31.
- Weichselbaum RR, Liang H, Deng L, et al: Radiotherapy and immunotherapy: A beneficial liaison? Nat Rev Clin Oncol 14:365-379, 2017.
- Golden EB, Pellicciotta I, Demaria S, et al. The convergence of radiation and immunogenic cell death signaling pathways. Front Oncol. 2012; 2: 88
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2019 Anales del Sistema Sanitario de Navarra
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
La revista Anales del Sistema Sanitario de Navarra es publicada por el Departamento de Salud del Gobierno de Navarra (España), quien conserva los derechos patrimoniales (copyright ) sobre el artículo publicado y favorece y permite la difusión del mismo bajo licencia Creative Commons Reconocimiento-CompartirIgual 4.0 Internacional (CC BY-SA 4.0). Esta licencia permite copiar, usar, difundir, transmitir y exponer públicamente el artículo, siempre que siempre que se cite la autoría y la publicación inicial en Anales del Sistema Sanitario de Navarra, y se distinga la existencia de esta licencia de uso.
